Join us in the new module of China [email protected] San Francisco: Medical Device Challenge, a complimentary medical device focused partnering and presenting meeting.

MyBioGate’s Medical Device Challenge Two is calling applications for reagents, instrumentations, as well as software services and technologies in the field of IVD.

According to the 2019 Bluebook for Medical Devices in China, the In-Vitro Diagnostics (IVD) market value in China equaled to $8.8 billion in 2018 at a growth rate of 18.42%, which is outperforming the growth rate of all regions in the global IVD market.

In addition, continuous healthcare reform promotes the development of the IVD market. Healthcare executives will start paying more attention to diagnostics to retain hospitals’ earnings by providing high-quality and customizable medical services, for which IVD is the key step.

Biochemical diagnosis, immunodiagnostics, and molecular diagnostics constitute 70% of China’s IVD market. While the market is seeking an integrated system as well as technology to speed up the testing of biochemical diagnosis. As for immunodiagnostics, high-quality technology will be the focal point for the strategic partnership.

On the other hand, investment in other relatively new areas, including microbiome diagnostics, liquid biopsy, and especially molecular diagnostics (sequencing) and POCT,  is growing rapidly and notably. 

Join us to meet with the major players and investors in China’s IVD market!

Deadline: 12/23/2019

Investors Apply

Projects Apply 

For more challenge area, please click here.